Joint EANM/SIOPE/RAPNO Practice Guidelines/SNMMI Procedure Standards for Imaging of Paediatric Gliomas Using PET with Radiolabelled Amino Acids and [F]FDG: Version 1.0

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2022 May 10

PMID 35536420

Authors

Arnoldo Piccardo

Nathalie L Albert

Lise Borgwardt

Frederic H Fahey

Darren Hargrave

Norbert Galldiks

Nina Jehanno

Lars Kurch

Ian Law

Ruth Lim

Egesta Lopci

Lisbeth Marner

Giovanni Morana

Tina Young Poussaint

Victor J Seghers

Barry L Shulkin

Katherine E Warren

Tatjana Traub-Weidinger

Pietro Zucchetta

Affiliations

Soon will be listed here.

Abstract

Positron emission tomography (PET) has been widely used in paediatric oncology. 2-Deoxy-2-[F]fluoro-D-glucose ([F]FDG) is the most commonly used radiopharmaceutical for PET imaging. For oncological brain imaging, different amino acid PET radiopharmaceuticals have been introduced in the last years. The purpose of this document is to provide imaging specialists and clinicians guidelines for indication, acquisition, and interpretation of [F]FDG and radiolabelled amino acid PET in paediatric patients affected by brain gliomas. There is no high level of evidence for all recommendations suggested in this paper. These recommendations represent instead the consensus opinion of experienced leaders in the field. Further studies are needed to reach evidence-based recommendations for the applications of [F]FDG and radiolabelled amino acid PET in paediatric neuro-oncology. These recommendations are not intended to be a substitute for national and international legal or regulatory provisions and should be considered in the context of good practice in nuclear medicine. The present guidelines/standards were developed collaboratively by the EANM and SNMMI with the European Society for Paediatric Oncology (SIOPE) Brain Tumour Group and the Response Assessment in Paediatric Neuro-Oncology (RAPNO) working group. They summarize also the views of the Neuroimaging and Oncology and Theranostics Committees of the EANM and reflect recommendations for which the EANM and other societies cannot be held responsible.

Citing Articles

LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals.

Achmad A, Hanaoka H, Holik H, Endo K, Tsushima Y, Kartamihardja A Theranostics. 2025; 15(5):1864-1878.

PMID: 39897549 PMC: 11780518. DOI: 10.7150/thno.99490.

Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?.

Vaz S, Groheux D, van Nijnatten T, Antunovic L, Cardoso F, Mottaghy F Eur J Nucl Med Mol Imaging. 2024; 52(3):801-805.

PMID: 39706898 DOI: 10.1007/s00259-024-07042-9.

Synthesis, preclinical assessment, and first-in-human study of [F]d-FET for brain tumor imaging.

Hou L, Chen Z, Chen F, Sheng L, Ye W, Dai Y Eur J Nucl Med Mol Imaging. 2024; 52(3):864-875.

PMID: 39482500 DOI: 10.1007/s00259-024-06964-8.

A New Tool for Extracting Static and Dynamic Parameters from [F]F-DOPA PET/CT in Pediatric Gliomas.

Mureddu M, Funck T, Morana G, Rossi A, Ramaglia A, Milanaccio C J Clin Med. 2024; 13(20).

PMID: 39458202 PMC: 11508825. DOI: 10.3390/jcm13206252.

Automatic detection and delineation of pediatric gliomas on combined [F]FET PET and MRI.

Ladefoged C, Henriksen O, Mathiasen R, Schmiegelow K, Andersen F, Hojgaard L Front Nucl Med. 2024; 2:960820.

PMID: 39354975 PMC: 11440972. DOI: 10.3389/fnume.2022.960820.

References

Harreld J, Doubrovin M, Butch E, Edwards A, Shulkin B . Developmental Venous Anomalies Mimicking Neoplasm on 11C-Methionine PET and DSC Perfusion MRI. Clin Nucl Med. 2017; 42(5):e275-e276. PMC: 5380515. DOI: 10.1097/RLU.0000000000001637. View

Holthoff V, Herholz K, Berthold F, Widemann B, Schroder R, Neubauer I . In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer. 1993; 72(4):1394-403. DOI: 10.1002/1097-0142(19930815)72:4<1394::aid-cncr2820720440>3.0.co;2-d. View

Paugh B, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J . Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010; 28(18):3061-8. PMC: 2903336. DOI: 10.1200/JCO.2009.26.7252. View

Cohen K, Jabado N, Grill J . Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?. Neuro Oncol. 2017; 19(8):1025-1034. PMC: 5570259. DOI: 10.1093/neuonc/nox021. View

Youland R, Kitange G, Peterson T, Pafundi D, Ramiscal J, Pokorny J . The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2012; 111(1):11-8. PMC: 3907171. DOI: 10.1007/s11060-012-0986-1. View

Singhal T, Narayanan T, Jacobs M, Bal C, Mantil J . 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012; 53(11):1709-15. DOI: 10.2967/jnumed.111.102533. View

Henriksen O, Marner L, Law I . Clinical PET/MR Imaging in Dementia and Neuro-Oncology. PET Clin. 2016; 11(4):441-52. DOI: 10.1016/j.cpet.2016.05.003. View

Gauvain K, Ponisio M, Barone A, Grimaldi M, Parent E, Leeds H . F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. Neurooncol Pract. 2018; 5(1):28-36. PMC: 5909807. DOI: 10.1093/nop/npx008. View

Kruer M, Kaplan A, Etzl Jr M, Carpentieri D, Dickman P, Chen K . The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood. J Neurooncol. 2009; 95(2):239-245. DOI: 10.1007/s11060-009-9922-4. View

10.

Ginet M, Zaragori T, Marie P, Roch V, Gauchotte G, Rech F . Integration of dynamic parameters in the analysis of F-FDopa PET imaging improves the prediction of molecular features of gliomas. Eur J Nucl Med Mol Imaging. 2019; 47(6):1381-1390. DOI: 10.1007/s00259-019-04509-y. View

11.

Stanescu L, Ishak G, Khanna P, Biyyam D, Shaw D, Parisi M . FDG PET of the brain in pediatric patients: imaging spectrum with MR imaging correlation. Radiographics. 2013; 33(5):1279-303. DOI: 10.1148/rg.335125152. View

12.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View

13.

Boellaard R, Rausch I, Beyer T, Delso G, Yaqub M, Quick H . Quality control for quantitative multicenter whole-body PET/MR studies: A NEMA image quality phantom study with three current PET/MR systems. Med Phys. 2015; 42(10):5961-9. DOI: 10.1118/1.4930962. View

14.

Juengling F, Kassubek J, Martens-Le Bouar H, Reinhardt M, Krause T, Nitzsche E . Cerebral regional hypometabolism caused by propofol-induced sedation in children with severe myoclonic epilepsy: a study using fluorodeoxyglucose positron emission tomography and statistical parametric mapping. Neurosci Lett. 2002; 335(2):79-82. DOI: 10.1016/s0304-3940(02)01060-1. View

15.

Reardon D, Ballman K, Buckner J, Chang S, Ellingson B . Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol. 2014; 16 Suppl 7:vii24-35. PMC: 4195531. DOI: 10.1093/neuonc/nou286. View

16.

Zukotynski K, Fahey F, Kocak M, Alavi A, Wong T, Treves S . Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2011; 52(2):188-95. PMC: 3526809. DOI: 10.2967/jnumed.110.081463. View

17.

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A . Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):83-103. DOI: 10.3322/caac.21219. View

18.

Ladefoged C, Andersen F, Kjaer A, Hojgaard L, Law I . RESOLUTE PET/MRI Attenuation Correction for O-(2-F-fluoroethyl)-L-tyrosine (FET) in Brain Tumor Patients with Metal Implants. Front Neurosci. 2017; 11:453. PMC: 5554515. DOI: 10.3389/fnins.2017.00453. View

19.

Morana G, Puntoni M, Garre M, Massollo M, Lopci E, Naseri M . Ability of (18)F-DOPA PET/CT and fused (18)F-DOPA PET/MRI to assess striatal involvement in paediatric glioma. Eur J Nucl Med Mol Imaging. 2016; 43(9):1664-72. DOI: 10.1007/s00259-016-3333-5. View

20.

Misch M, Guggemos A, Hernaiz Driever P, Koch A, Grosse F, Steffen I . (18)F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors. Childs Nerv Syst. 2014; 31(2):261-7. DOI: 10.1007/s00381-014-2552-y. View